Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregonda: RO7497372 in Diabetic Macular Edema
NCT06847854Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Dec 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of RO7497372 in diabetic macular edema (DME) (3 arms), sponsored by Genentech. Primary endpoints: Number of Participants With Adverse Events at 56 weeks, Number of Participants With Intraocular Inflammation AEs at 48 weeks and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
RO7497372
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06847854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847854.